Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Vitamin C may increase the effectiveness of arsenic trioxide by
making cancer cells more sensitive to the drug.
PURPOSE: Phase I/II trial to determine the effectiveness of arsenic trioxide plus vitamin C
in treating patients who have recurrent or refractory multiple myeloma.